By The Life Science Report
Source: Streetwise Reports 09/04/2019
The study data and their implications are provided in a BTIG report.
In an Aug. 29 research note, BTIG analyst Thomas Shrader reported that just released topline data are “as hoped” from Esperion Therapeutics Inc.’s (ESPR:NASDAQ) Phase 2 trial of bempedoic acid-ezetimibe combination therapy in patients with hypercholesterolemia and type 2 diabetes.
Shrader relayed the results, which were from the study’s 12-week point.
Get our Weekly Commitment of Traders Report: - See where the biggest traders (Hedge Funds and Commercial Hedgers) are positioned in the futures markets on a weekly basis.
Get Our Free Metatrader 4 Indicators - Put Our Free MetaTrader 4 Custom Indicators on your charts when you join our Weekly Newsletter
The trial met primary and key secondary endpoints. For one, low density lipoprotein (LDL) cholesterol dropped “an impressive” 40% versus 20% in patients getting ezetimibe alone. HsCRP decreased 25%. Glycemic control did not worsen, and there were no increases in adverse events.
In about 40% of the patients, LDL cholesterol decreased by more than 50% to levels under 70 milligrams per deciliter. This compares to about 5% in the ezetimibe-only cohort. These combination patients also experienced 27% reductions in total cholesterol and ApoB along with a 33% drop in non-high density lipoprotein (HDL) cholesterol.
What this means, highlighted Shrader, is the bempedoic acid combination got “two times the number of patients to a moderately better place (LDL cholesterol less than 100) and nearly eight times the patients to the new happy zone (LDL cholesterol lower than 70).” In other words, 20% of the market is not achieving the latter.
Shrader pointed out that “a potentially a nice attribute of” bempedoic acid is it might be a better choice for people on the cusp of developing type 2 diabetes because other statins at high doses tend to increase HbA1c. However, “a lot more work needs to be done to establish this claim,” he added.
Esperion is currently working with payers to get the drug into the lowest co-pay tiers, noted Shrader. “We see these negotiations with payers as important and a key read on market ‘pull’ for bempedoic acid.”
BTIG has a Buy rating and an $82 per share target price on Esperion. The stock is currently trading at around $33.59 per share.
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
Disclosures from BTIG, Esperion Therapeutics Inc., August 29, 2019
Analyst Certification I, Thomas Shrader, PhD, CFA, hereby certify that the views about the companies and securities discussed in this report are accurately expressed and that I have not received and will not receive direct or indirect compensation in exchange for expressing specific recommendations or views in this report.
I, Julian Harrison, hereby certify that the views about the companies and securities discussed in this report are accurately expressed and that I have not received and will not receive direct or indirect compensation in exchange for expressing specific recommendations or views in this report.
The research analyst(s) responsible for the preparation of this report receives compensation based upon a variety of factors, including the quality and accuracy of research, internal/client feedback, and overall Firm revenues.
( Companies Mentioned: ESPR:NASDAQ,